Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
- Conditions
- Interventions
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT00088218
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 410
- Registration Number
- NCT00002925
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-12-23
- Target Recruit Count
- 1520
- Registration Number
- NCT00002549
- Locations
- 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002502
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002691
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱Clinica Alemana, Santiago, Chile
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 60
- Registration Number
- NCT00004192
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: cytarabineDrug: dexamethasoneDrug: etoposideDrug: idarubicinDrug: ifosfamideDrug: leucovorin calciumDrug: mesnaDrug: pegaspargaseDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapyDrug: Methotrexate
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Kaplan Cancer Center, New York, New York, United States
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
- Conditions
- Interventions
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 20
- Registration Number
- NCT00002657
- Locations
- 🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸CCOP - Dayton, Kettering, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 55
- Registration Number
- NCT00004217
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.